Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XORTX TherapeuticsXRTX +7.44%32 3-Year EBITDA Growth Rate is 54.20% as of Jun. 2026, which is 1836% above its 10-year median of 2.80. GuruFocus rates XRTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, XORTX Therapeutics ranks better than 88.2% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of XORTX Therapeutics was 54.20% per year. The lowest was -127.10% per year. And the median was 2.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
XORTX Therapeutics 3-Year EBITDA Growth Rate Related Terms
XRTX vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, XORTX Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XORTX Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where XORTX Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.20% mean?
XORTX Therapeutics (XRTX) has a 3-Year EBITDA Growth Rate of 54.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for XORTX Therapeutics and its competitors. This is 1836% above median its historical median of 2.80. According to the industry distribution chart, XORTX Therapeutics ranks #133 out of 1127 companies in the Biotechnology industry, placing it in the top 11.8%.
Is XORTX Therapeutics' 3-Year EBITDA Growth Rate too high?
XORTX Therapeutics' current 3-Year EBITDA Growth Rate of 54.20% is 1836% above median its 10-year median of 2.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. XORTX Therapeutics' value of 54.20% is 271.2% above this industry median. Based on the distribution chart, XORTX Therapeutics ranks #133 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, XORTX Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XORTX Therapeutics ranks #133 out of 1127 companies for 3-Year EBITDA Growth Rate. This places XORTX Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. XORTX Therapeutics' value of 54.20% is 271.2% above this benchmark. While the company's 10-year median is 2.80 vs. the industry median of 14.60, XORTX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XORTX Therapeutics's current 3-Year EBITDA Growth Rate of 54.20% is 271.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for XORTX Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XORTX Therapeutics's current 3-Year EBITDA Growth Rate is 54.20%, which is 1836% above median its own 10-year median of 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (XRTX) has a current 3-Year EBITDA Growth Rate of 54.20%. The current 3-Year EBITDA Growth Rate is 54.20%, which is 1836% above median its 10-year median of 2.80 and 271.2% above the Biotechnology industry median of 14.60. XORTX Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For XORTX Therapeutics (XRTX), the current 3-Year EBITDA Growth Rate is 54.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
32GF Score
Get the complete analysis for XRTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XRTX has been successfully added to your 
